Core Viewpoint - 泰德医药's stock is currently in a downtrend, having reached its lowest price since listing, indicating potential concerns regarding its market performance and investor confidence [1]. Group 1: Stock Performance - 泰德医药's stock closed at 27.28 HKD, with a decline of 2.502% on the day [1]. - The stock hit a low of 25.78 HKD during trading, marking the lowest price since its IPO [1]. - Since its listing, 泰德医药 has experienced a cumulative decline of 10.85% [1]. Group 2: IPO Details - 泰德医药 was listed on the Hong Kong Stock Exchange on June 30, 2025, with a final offer price of 30.6 HKD per share [1]. - A total of 16,800,000 H-shares were issued, with 8,400,000 shares allocated for public offering in Hong Kong and 8,400,000 shares for international offering [1]. - The total proceeds from the IPO amounted to 514.08 million HKD, with net proceeds of 428.77 million HKD after deducting estimated listing expenses of 85.31 million HKD [1]. Group 3: Underwriters and Investors - The joint sponsors and underwriters for 泰德医药 include Morgan Stanley, CITIC Securities, and others [1]. - Key cornerstone investors for 泰德医药 are 石药 and Welight Capital [2].
港股破发股泰德医药跌2.5%创新低 上市募5.14亿港元